Probatebeta
Target

TGFB1

Transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated peptide

As of the edition of 20 October 2026, TGFB1 (transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated peptide, UniProt P01137) has 13 drugs tested at it and 16 companies on the list, 7 on route A and 1 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P01137
How well studied
Biology documented; no tool compounds or approved drug yet
Where it sits in the cell
Secreted
Solved structures
22
Disease areas
Cancer; Blood and lymph; Inherited and neonatal; Digestive system; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Skin and connective tissue
Registered trials of its drugs
173

Drugs at this target

StatusCount
Marketed1
Active3
Went quiet1
Stopped6
Status not established2
Total13
DrugStatusFurthest phaseUS protection
LuspaterceptMarketedPhase 4Ends 2031
Bintrafusp alfaStoppedPhase 3none listed
FresolimumabStoppedPhase 2none listed
NisevokitugStoppedPhase 3none listed
STP705StoppedPhase 2none listed
TQB2858StoppedPhase 2none listed
ES014ActivePhase 2none listed
SAR-439459ActivePhase 2none listed
DR30206ActivePhase 2none listed
DisitertideWent quietPhase 2none listed
BPB-101Status not establishedPhase 2none listed
LY-2382770StoppedPhase 2none listed

12 of 13 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A7
Route B1
Engaged4
Undetermined4
Total on the list16
Three companies on route A or B, with the route only
CompanyRoute
Bristol Myers SquibbRoute B
NovartisRoute A
Eli LillyRoute A

The other 13 companies at TGFB1

In the product

16 companies in all; 13 are not named here, and no score is.

See the 16 companies at TGFB1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in cancer